Liver: Spiral CT of the Liver: Pressing the CT Envelope
Elliot K. Fishman, M.D., FACRProfessor of Radiology and Oncology Johns Hopkins University School of Medicine IntroductionThe liver has always been the organ that has provided the greatest challenge to the radiologist and referring physician. Whether the imaging modality be CT, MRI, ultrasound or angiography, questions of lesion detection rates (including both false-positive and negative studies) as well as lesion discrimination have always been the focus of heated debate. Lesion detection rates have varied depending on the study protocols used (including various scanners and their capabilities) as well as pathology studied (i.e. metastases from colon cancer vs. hepatoma in a cirrhotic liver). A review of many of the prior studies is far beyond the scope of this article or the time allotted for this discussion. Nevertheless most studies found CT to only be in the detection range of 50-80% for liver tumors. A specific form of CT called CTAP (Computed Tomographic Angiographic Portography) which involved placing a catheter into the SMA, became the gold standard but still was little more than 80% accurate in most studies. Techniques of combining CTA and CTAP were even attempted to try to raise lesion detection levels. A problem with both CTA and CTAP were flow related defects that could result in either false-positive studies or in over-estimation of tumor extent in up to 15% of cases. Published ReportsThe published reports of spiral CT for the detection of liver tumors have been better than any other modality to date. Some of the recent results have included a better than 90% detection rate for lesions with portal phase imaging alone in one series of 21 patients. Addition of arterial phase imaging increased lesion detection by around 9% compared to when portal phase imaging alone was performed. Obviously the success of lesion detection and the role of arterial and portal phase imaging will depend in part on the patient population (i.e. metastatic colon cancer vs. hepatoma) studied as well as the status of the underlying liver parenchyma (i.e. normal liver vs. cirrhosis). Some conclusions from recent published reports include:
ProtocolsIn terms of study protocol, the question based on published data is when to do portal phase examinations of the liver, when to do arterial phase examinations of the liver and when to do both. In principle, the single best examination technique for the liver would include non-contrast examination, followed by arterial and portal phase imaging (some might even suggest delayed scans following equilibrium as well). However, this is not truly practical in a busy clinical practice, both from time of study perspective as well as from a cost-efficiency basis. Our routine protocol then is to triage patients into various categories and tailor examinations accordingly. Some of the protocols are: (a) rule out liver metastases in a patient with colon cancer: portal phase imaging (b) evaluate islet cell tumor of the pancreas and extent of liver involvement: arterial phase imaging (c) rule out hepatoma in a cirrhotic liver: arterial and portal phase imaging (d) evaluate patient for potential liver transplant: arterial and portal phase imaging (e) preoperative evaluation of the liver prior to surgical resection: arterial and portal phase imaging The goal of these protocols is to provide the information needed as efficiently as possible in a real world setting. Specific scanning protocols will vary from scanner to scanner and manufacturer to manufacturer but certain principles are common. The ideal study requires narrow collimation, close interscan spacing but at a mAs that is comparable to non-spiral studies. Recent advances in tube and generator technology have made this possible. Some sample protocols as used on Siemens Somatom Plus-4 (Siemens Medical Systems, Iselin, NJ) include: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
PitfallsSome of the pitfalls of spiral CT of the liver include:
Future DirectionsThe current success with spiral CT imaging of the liver will be a focal point of further research and technical developments. These include;(1) continuing studies will be published defining how to optimize lesion detection/definition with spiral CT. The need for single vs. dual phase studies will continue to be defined for specific tumors. The success rate for spiral CT vs. other imaging techniques (especially MRI) will continue to be addressed. (2) technical developments will allow for better on-line real time monitoring of contrast injections building on the initial positive results from Smart-Prep (GE Medical Systems). The CARE program from Siemens Medical Systems may be one step in that direction. (3) 3D imaging of the liver will flourish with automated organ segmentation schemes and optimization of display of vascular maps. (4) blood pool contrast agents may become available and will potentially increase lesion discrimination (cyst vs. malignancy). Parenchymal Liver DiseaseSpiral CT has all of the advantages of dynamic CT in the evaluation of parenchymal liver disease, but all provide some distinct advantages. These advantages center around rapid data acquisition, coupled with the ability to optimize the timing between contrast injection and data acquisition. Just as these advantages can help increase lesion detection when discussing tumors they also can be useful in other applications including;
A full in-depth discussion of all of these entities is impossible but some key points include;
References1. Oi H, Murakami T, Kim T, Matsushita M, Kashimoto H, Nakamura H. Dynamic MR imaging and early-phase helical CT for detecting small intrahepatic metastases of hepatocellular carcinoma. AJR 1996;166:369-374.2. Oliver JH III, Baron RL, Federle MP, Rockette HE Jr. Detecting hepatocellular carcinoma: Value of unenhanced or arterial phase CT imaging or both used in conjunction with conventional portal venous phase contrast-enhanced CT imaging. AJR 1996;167:71-77. 3. Kuszyk BS, Bluemke DA, Urban BA, Choti MA, Hruban RH, Sitzmann JV, Fishman EK. Portal-phase contrast-enhanced helical CT for the detection of malignant hepatic tumors: Sensitivity based on comparison with intraoperative and pathologic findings. AJR 1996;166-91-95. 4. Baron RL, Oliver JH III, Dodd GD III, Nalesnik M, Holbert BL, Carr B. Hepatocellular carcinoma: Evaluation with biphasic contrast-enhanced helical CT. Radiology 1996;199:505-511. 5. Semelka RC, Schlund JF, Molina PL, Willms AB, Kahlenberg M, MauroMauro MA, Weeks SM, Gance WG. Malignant liver lesions: Comparison of spiral CT arterial portography and MR imaging for diagnostic accuracy, cost, and effect on patient management. JMRI 1996;1:39-43. 6. Yamashita Y, Mitsuzaki K, Yi T, Ogata I, Nishiharu T, Urata J, Takahashi M. Small hepatocellular carcinoma in patients with chronic;liver damage: Prospective comparison of detection with dynamic MR imaging and helical CT of the whole liver. Radiology 1996;200:79-84. 7. Irie T and Kusano S. Contrast-enhanced spiral CT of the liver: Effect of injection time on time to peak hepatic enhancement. J Comput Assist Tomogr 1996;20(4):633-637. 8. Bonaldi VM, Bret PM, Reinhold C, Atri M. Helical CT of the liver: Value of an early hepatic arterial phase. Radiology 1995;197:357-363. 9. Kanematsu M, Imaeda T, Mizuno S, Yamawaki Y, Sone Y, Iida T, Kato M, Yokoyama R. Value of three-dimensional spiral CT hepatic angiography. AJR 1996;166:585-591. 10. Frederick MG, McElaney BL, Singer A, Park KS, Paulson EK, McGee SG, Nelson RC. Timing of parenchymal enhancement on dual-phase dynamic helical CT of the liver: How long does the hepatic arterial phase predominate? AJR 1996;166:1305-1310. 11. Lin JP and Lu DSK. Early enhancement of tumor thrombus in portal vein on two-phase helical CT. J Comput Assist Tomogr 1996;20(4):653-655. 12. Lupetin AR, Cammisa BA, Beckman I, Dash N, Khoury MB, Kiproff PM, McKenzie RS. Spiral CT during arterial portography. RadioGraphics 1996;16:723-743. 13. Herts BR, Baker ME, Davros WJ, Lorig RJ, Obuchowski N, Shiesly DA, Roelke D. Helical CT of the abdomen: Comparison of image quality between scan times of 0.75 and 1 Sec per revolution. AJR 1996;167:58-60. 14. Silverman PM, Roberts SC, Ducic I, Tefft MC, Olson MC, Cooper C, Zeman RK. Assessment of a technology that permits individualized scan delays on helical hepatic CT: A technique to improve efficiency in use of contrast;material. AJR 1996;167:79-84. 15. Oliver JH III, Baron RL, Federle MP, Rockette HE Jr. Detecting hepatocellular carcinoma: Value of unenhanced or arterial phase CT imaging or both used in conjunction with conventional portal venous phase contrast-enhanced CT imaging. AJR 1996;167:71-77. |